|
2025
|
P/S
|
Pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in treating ... |
|
2024
|
P/S
|
Administration services related to patient support program that helps patients, in coordination w... |
|
|
Invention
|
Somatostatin subtype receptor 3 (sstr3) agonists and uses thereof. Described herein are compounds... |
|
|
Invention
|
Nonpeptide somatostatin type 5 receptor agonists and uses thereof.
Described herein are compound... |
|
|
P/S
|
Business administration of a patient support program that helps patients, in coordination with th... |
|
|
Invention
|
Uses of a somatostatin modulator for the treatment of disease.
Described herein are formulations... |
|
|
Invention
|
Compositions and methods for the treatment of congenital adrenal hyperplasia. Provided are compos... |
|
|
Invention
|
Melanocortin subtype-2 receptor (mc2r) antagonist for the treatment of acth-dependent cushing's s... |
|
|
Invention
|
Compositions and methods for administering paltusotine to patients with hepatic impairment. Provi... |
|
|
Invention
|
Formulations of a somatostatin modulator.
Described herein are formulations of a somatostatin mo... |
|
|
Invention
|
Process of making somatostatin modulators.
Described herein are compounds that are somatostatin ... |
|
|
Invention
|
Somatostatin subtype-2 receptor (sst2r) targeted therapeutics and uses thereof. Described herein ... |
|
2023
|
Invention
|
Crystalline melanocortin subtype-2 receptor (mc2r) antagonist.
Described herein are crystalline ... |
|
|
Invention
|
Crystalline melanocortin subtype-2 receptor (mc2r) antagonist. Described herein are crystalline f... |
|
|
Invention
|
Somatostatin subtype-2 receptor (sst2r) targeted therapeutics and uses thereof.
Described herein... |
|
|
Invention
|
Melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof.
Described herein are compou... |
|
|
P/S
|
Pharmaceutical preparations for human use |
|
|
P/S
|
Pharmaceutical preparations for human use. |
|
|
P/S
|
Pharmaceutical preparations for modulating neuropeptides and G-protein coupled receptors (GPCRs);... |
|
|
Invention
|
Treatment of congenital adrenal hyperplasia and polycystic ovary syndrome. The instant disclosure... |
|
|
Invention
|
Uses of a somatostatin modulator for the treatment of carcinoid syndrome.
Described herein are u... |
|
|
Invention
|
Uses of a somatostatin modulator for the treatment of carcinoid syndrome. Described herein are us... |
|
2022
|
Invention
|
Parathyroid hormone (pth) receptor antagonists and uses thereof.
Described herein are compounds ... |
|
|
Invention
|
Parathyroid hormone (pth) receptor antagonists and uses thereof. Described herein are compounds t... |
|
|
Invention
|
Somatostatin modulators and uses thereof.
Described herein are compounds that are somatostatin m... |
|
|
Invention
|
Non-peptide targeted therapeutics and uses thereof.
Described herein are non-peptide drug conjug... |
|
|
Invention
|
Non-peptide targeted therapeutics and uses thereof. Described herein are non-peptide drug conjuga... |
|
|
Invention
|
Uses of a somatostatin modulator for the treatment of disease. Described herein are formulations ... |
|
|
Invention
|
Somatostatin modulators and uses thereof. Described herein are compounds that are somatostatin mo... |
|
|
Invention
|
Melanocortin subtype-2 receptor (mc2r) antagonist for the treatment of disease. Provided herein a... |
|
|
Invention
|
Somatostatin receptor type 5 agonist for the treatment of hyperinsulinism.
Provided herein are m... |
|
|
Invention
|
Crystalline forms of a somatostatin modulator. Described herein are crystalline forms of 4-[(3S)-... |
|
|
Invention
|
Somatostatin receptor type 5 agonist for the treatment of hyperinsulinism. Provided herein are me... |
|
|
Invention
|
Formulations of a somatostatin modulator. Described herein are formulations of a somatostatin mod... |
|
2021
|
Invention
|
Formulations of a somatostatin modulator. A spray-dried solid dispersion comprising: (a) 3 - [4 -... |
|
2020
|
Invention
|
Gem-disubstituted piperidine melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof.... |
|
|
Invention
|
Spirocyclic piperidine melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof.
Desc... |
|
|
Invention
|
Crystalline forms of somatostatin modulators.
Described herein are pharmaceutically acceptable s... |
|
2018
|
P/S
|
Medical and pharmaceutical research services; pharmaceutical research and development; research a... |
